High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group

B Kasenda; G Ihorst; R Schroers; A Korfel; I Schmidt-Wolf; G Egerer; L von Baumgarten; A Röth; J Bloehdorn; R Möhle; M Binder; U Keller; M Lamprecht; M Pfreundschuh; E Valk; H Fricker; E Schorb; K Fritsch; J Finke; G Illerhaus

doi:10.1038/leu.2017.170

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group

Standard

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group. / Kasenda, B; Ihorst, G; Schroers, R; Korfel, A; Schmidt-Wolf, I; Egerer, G; von Baumgarten, L; Röth, A; Bloehdorn, J; Möhle, R; Binder, M; Keller, U; Lamprecht, M; Pfreundschuh, M; Valk, E; Fricker, H; Schorb, E; Fritsch, K; Finke, J; Illerhaus, G.

in: LEUKEMIA, Jahrgang 31, Nr. 12, 12.2017, S. 2623-2629.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kasenda, B, Ihorst, G, Schroers, R, Korfel, A, Schmidt-Wolf, I, Egerer, G, von Baumgarten, L, Röth, A, Bloehdorn, J, Möhle, R, Binder, M, Keller, U, Lamprecht, M, Pfreundschuh, M, Valk, E, Fricker, H, Schorb, E, Fritsch, K, Finke, J & Illerhaus, G 2017, 'High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group', LEUKEMIA, Jg. 31, Nr. 12, S. 2623-2629. https://doi.org/10.1038/leu.2017.170

APA

Kasenda, B., Ihorst, G., Schroers, R., Korfel, A., Schmidt-Wolf, I., Egerer, G., von Baumgarten, L., Röth, A., Bloehdorn, J., Möhle, R., Binder, M., Keller, U., Lamprecht, M., Pfreundschuh, M., Valk, E., Fricker, H., Schorb, E., Fritsch, K., Finke, J., & Illerhaus, G. (2017). High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group. LEUKEMIA, 31(12), 2623-2629. https://doi.org/10.1038/leu.2017.170

Vancouver

Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group. LEUKEMIA. 2017 Dez;31(12):2623-2629. https://doi.org/10.1038/leu.2017.170

Bibtex

@article{83e10592cb5647d98834df1b87706706,

title = "High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group",

abstract = "To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain, Central Nervous System Neoplasms, Combined Modality Therapy, Drug Resistance, Neoplasm, Female, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Male, Middle Aged, Prospective Studies, Recurrence, Retreatment, Transplantation, Autologous, Treatment Outcome, Clinical Trial, Phase II, Journal Article, Multicenter Study",

author = "B Kasenda and G Ihorst and R Schroers and A Korfel and I Schmidt-Wolf and G Egerer and {von Baumgarten}, L and A R{\"o}th and J Bloehdorn and R M{\"o}hle and M Binder and U Keller and M Lamprecht and M Pfreundschuh and E Valk and H Fricker and E Schorb and K Fritsch and J Finke and G Illerhaus",

year = "2017",

month = dec,

doi = "10.1038/leu.2017.170",

language = "English",

volume = "31",

pages = "2623--2629",

journal = "LEUKEMIA",

issn = "0887-6924",

publisher = "NATURE PUBLISHING GROUP",

number = "12",

}

RIS

TY - JOUR

T1 - High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group

AU - Kasenda, B

AU - Ihorst, G

AU - Schroers, R

AU - Korfel, A

AU - Schmidt-Wolf, I

AU - Egerer, G

AU - von Baumgarten, L

AU - Röth, A

AU - Bloehdorn, J

AU - Möhle, R

AU - Binder, M

AU - Keller, U

AU - Lamprecht, M

AU - Pfreundschuh, M

AU - Valk, E

AU - Fricker, H

AU - Schorb, E

AU - Fritsch, K

AU - Finke, J

AU - Illerhaus, G

PY - 2017/12

Y1 - 2017/12

N2 - To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting.

AB - To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Brain

KW - Central Nervous System Neoplasms

KW - Combined Modality Therapy

KW - Drug Resistance, Neoplasm

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Lymphoma

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Recurrence

KW - Retreatment

KW - Transplantation, Autologous

KW - Treatment Outcome

KW - Clinical Trial, Phase II

KW - Journal Article

KW - Multicenter Study

U2 - 10.1038/leu.2017.170

DO - 10.1038/leu.2017.170

M3 - SCORING: Journal article

C2 - 28559537

VL - 31

SP - 2623

EP - 2629

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 12

ER -